Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases

J Clin Oncol. 2018 Apr 1;36(10):1051. doi: 10.1200/JCO.2017.77.0115. Epub 2018 Feb 1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bone Density Conservation Agents*
  • Breast Neoplasms*
  • Cost-Benefit Analysis
  • Denosumab
  • Diphosphonates
  • Female
  • Humans
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Denosumab
  • Zoledronic Acid